286 related articles for article (PubMed ID: 38005859)
1. COVID-19 Incidence Proportion as a Function of Regional Testing Strategy, Vaccination Coverage, and Vaccine Type.
Totolian AA; Smirnov VS; Krasnov AA; Ramsay ES; Dedkov VG; Popova AY
Viruses; 2023 Oct; 15(11):. PubMed ID: 38005859
[No Abstract] [Full Text] [Related]
2. SARS-CoV-2 incidence, seroprevalence, and COVID-19 vaccination coverage in the homeless population: a systematic review and meta-analysis.
Liang Y; Sun Q; Liu Q; Pang Y; Tang S
Front Public Health; 2023; 11():1044788. PubMed ID: 37900041
[TBL] [Abstract][Full Text] [Related]
3. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia.
McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC
Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236
[TBL] [Abstract][Full Text] [Related]
4. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
5. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
6. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
7. Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis.
COVID-19 Cumulative Infection Collaborators
Lancet; 2022 Jun; 399(10344):2351-2380. PubMed ID: 35405084
[TBL] [Abstract][Full Text] [Related]
8. Can we get out of the COVID pandemic without adequate vaccination coverage in the pediatric population?
Esposito S; Giordano R; Paini G; Puntoni M; Principi N; Caminiti C
Ital J Pediatr; 2022 Aug; 48(1):150. PubMed ID: 35986340
[TBL] [Abstract][Full Text] [Related]
9. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
10. Optimal SARS-CoV-2 vaccine allocation using real-time attack-rate estimates in Rhode Island and Massachusetts.
Tran TN; Wikle NB; Albert E; Inam H; Strong E; Brinda K; Leighow SM; Yang F; Hossain S; Pritchard JR; Chan P; Hanage WP; Hanks EM; Boni MF
BMC Med; 2021 Jul; 19(1):162. PubMed ID: 34253200
[TBL] [Abstract][Full Text] [Related]
11. Coverage and Estimated Effectiveness of mRNA COVID-19 Vaccines Among US Veterans.
Young-Xu Y; Korves C; Roberts J; Powell EI; Zwain GM; Smith J; Izurieta HS
JAMA Netw Open; 2021 Oct; 4(10):e2128391. PubMed ID: 34613401
[TBL] [Abstract][Full Text] [Related]
12. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.
Shrotri M; Krutikov M; Palmer T; Giddings R; Azmi B; Subbarao S; Fuller C; Irwin-Singer A; Davies D; Tut G; Lopez Bernal J; Moss P; Hayward A; Copas A; Shallcross L
Lancet Infect Dis; 2021 Nov; 21(11):1529-1538. PubMed ID: 34174193
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
Oda Y; Kumagai Y; Kanai M; Iwama Y; Okura I; Minamida T; Yagi Y; Kurosawa T; Greener B; Zhang Y; Walson JL
Lancet Infect Dis; 2024 Apr; 24(4):351-360. PubMed ID: 38141632
[TBL] [Abstract][Full Text] [Related]
14. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex.
Patone M; Mei XW; Handunnetthi L; Dixon S; Zaccardi F; Shankar-Hari M; Watkinson P; Khunti K; Harnden A; Coupland CAC; Channon KM; Mills NL; Sheikh A; Hippisley-Cox J
Circulation; 2022 Sep; 146(10):743-754. PubMed ID: 35993236
[TBL] [Abstract][Full Text] [Related]
15. Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.
Ng OT; Marimuthu K; Lim N; Lim ZQ; Thevasagayam NM; Koh V; Chiew CJ; Ma S; Koh M; Low PY; Tan SB; Ho J; Maurer-Stroh S; Lee VJM; Leo YS; Tan KB; Cook AR; Tan CC
JAMA Netw Open; 2022 Aug; 5(8):e2228900. PubMed ID: 36018588
[TBL] [Abstract][Full Text] [Related]
16. The COVID-19 Vaccination and Vaccine Inequity Worldwide: An Empirical Study Based on Global Data.
Ning C; Wang H; Wu J; Chen Q; Pei H; Gao H
Int J Environ Res Public Health; 2022 Apr; 19(9):. PubMed ID: 35564661
[TBL] [Abstract][Full Text] [Related]
17. Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries.
Hussain A; Rafeeq H; Asif HM; Shabbir S; Bilal M; Mulla SI; Franco M; Iqbal HMN
Int Immunopharmacol; 2021 Oct; 99():108050. PubMed ID: 34426120
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Vaccination Worldwide on SARS-CoV-2 Infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants.
Damasceno DHP; Amaral AA; Silva CA; Simões E Silva AC
Curr Med Chem; 2022; 29(15):2673-2690. PubMed ID: 34473613
[TBL] [Abstract][Full Text] [Related]
19. A flexible age-dependent, spatially-stratified predictive model for the spread of COVID-19, accounting for multiple viral variants and vaccines.
Schneider KA; Tsoungui Obama HCJ; Adil Mahmoud Yousif N
PLoS One; 2023; 18(1):e0277505. PubMed ID: 36662784
[TBL] [Abstract][Full Text] [Related]
20. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
